Physician profile
Tedra D Gray
NPI 1659358760
$77,568.54
in general payments reported to CMS, 2019-2025
37 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,098 · 2022: $7,160 · 2023: $7,445 · 2024: $24K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $15K · Food and Beverage: $9,850 · Consulting Fee: $9,153 · Honoraria: $3,478 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,893.67 |
| Travel and Lodging | $14,857.72 |
| Food and Beverage | $9,849.86 |
| Consulting Fee | $9,153.25 |
| Honoraria | $3,477.50 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $22,752.23 | 2023-2025 | Dupixent, Libtayo |
| Phathom Pharmaceuticals, INC. | $17,494.83 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $11,224.24 | 2021-2023 | Gimoti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10,114.59 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $6,443.58 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $2,550.81 | 2021-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,434.00 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,043.80 | 2021-2025 | Entyvio, Fruzaqla, Alunbrig |
| Janssen Biotech, INC. | $799.59 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $453.76 | 2021-2025 | Omvoh, Jaypirca, Verzenio |
| Mahana Therapeutics, INC. | $405.00 | 2022 | |
| Abbvie INC. | $401.54 | 2021-2025 | |
| Celgene Corporation | $332.91 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $285.51 | 2025 | Rezdiffra |
| Modernatx, INC. | $250.00 | 2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tedra Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.